Comparative effectiveness: Its role in the healthcare system

Current Opinion in Ophthalmology

Volumn 20, Issue 3, 2009, Pages 188-194

  Brown, Melissa M ^a,b,c,d,g   Luo, Betsy ^a,e   Brown, Heidi C ^a   Brown, Gary C ^a,c,f  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Eye Research Institute   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g NONE   (United States)

Author keywords

Comparative effectiveness; Cost effectiveness; Utility analysis; Value based medicine

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAPTANIB; PROTON PUMP INHIBITOR; RANIBIZUMAB; SEROTONIN UPTAKE INHIBITOR;

COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; EVIDENCE BASED PRACTICE; FINANCIAL MANAGEMENT; GASTROESOPHAGEAL REFLUX; HAY FEVER; HEALTH CARE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LAW; MEDICAL RESEARCH; METHODOLOGY; OSTEOPOROSIS; PHYSICIAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SUBRETINAL NEOVASCULARIZATION; UNITED STATES; COST BENEFIT ANALYSIS; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 65549090090     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328329cd59     Document Type: Review

References (23)

1. Mitka M. Comparative effectiveness. JAMA 2008; 300:1290.
2. Senate Bill S.3408. http://thomas.loc.gov/cgi-bin/thomas. [Accessed 10 January 2009]
3. Obama '08. Barack Obama's Plan for a Healthy America: lowering healthcare costs and ensuring high-quality affordable healthcare for all. http://www.barackobama.com/pdf/HealthPlanFull.pdf. [Accessed on 10 January 2009] This document outlines the healthcare philosophy of the President, much of which could theoretically be enacted, as the same political party occupies the Presidency, Senate, and House of Representatives.
4. Senate Bill 3408. Comparative Effectiveness Research Act of 2008. http://thomas.loc.gov/cgi-bin/query/F?c110:1 :./temp/~d 109bCK2c:e1187.[Accessed 10 January 2009] This reference addresses the activities of a nongovernment-affiliated Healthcare Comparative Effectiveness Research Institute. It also familiarizes the reader with the critically important Thomas.loc.gov website where the status of any Congressional bill can be investigated.
5. Senate Bill S.3408. Comparative Effectiveness Research Act of 2008. SEC. 9511. Comparative Effectiveness Research Trust Fund, http://thomas.loc. gov/cgi-bin/query/F?c110:1 :./temp/~c110MUiGXb:e47557. [Accessed 10 January 2009]
6. Brown MM, Brown GC, Sharma S. Evidence-based to value-based medicine. Chicago: AMA Press; 2005:; pp. 1 -324.
7. National Institute for Health and Clinical Excellence (NICE). Incorporating health economics in guidelines and assessing resource impact. The Guidelines Manual. London: NICE; 2007, chapter 8. http://www.nice.org.uk/ page.aspx?o=422950. [Accessed 15 March 2008]
8. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999; 97:473-512.
9. Brown GC, Sharma S, Brown MM, Kistler J. Utility values associated with age- related macular degeneration. Arch Ophthalmol 2000; 118:47-51.
10. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol 1999; 128:324-330.
11. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001; 85:327-331.
12. Ahmed A. American College of Cardiology/American Heart Association chronic heart failure evaluation and management guidelines: relevance to the geriatric practice. Am J Geriatr Soc 2003; 51:1 -126.
13. Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration. Perceptions of patients, clinicians and community members. Br J Ophthalmol 2003; 87:8-12.
14. Klarman H, Francis J, Rosenthal G. Cost-effectiveness applied to the treatment of chronic renal disease. Med Care 1968; 6:48-55.
15. Merriam-Webster's Online Dictionary, http://www.merriam-webster.com/dic- tionary/value. [Accessed 11 January 2009]
16. Brown MM, Brown GC, Sharma S, Landy J. Healthcare economic analyses and value-based medicine. Surv Ophthalmol 2003; 48:204-223.
17. Brown MM, Brown GC, Sharma S. Value-based medicine. A paradigm for quality pharmaceutical care. Drug Benefit Trends 2006; 18:285-289.
18. Brown GC, Brown MM, Brown H, Peet JS. A value-based medicine analysis of ranibizumab (MARINA Study) for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115:1039-1045. This report is representative of a value-based medicine cost-utility analysis, the results of which can theoretically be compared with the value and cost-utility of interventions across all of medicine.
19. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1339-1341.
20. Drummond ME, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of healthcare programmes. 2nd ed. New York: Oxford University Press; 1999.
21. 90Sr brachytherapy/intravitreal VEGF inhibitor for neovascular macular degeneration. Evidence Based Ophthalmol (in press).
22. Brown GC, Brown MM, Sharma S. Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration. Can J Ophthalmol 2000; 35:27-32.
23. The World Health Organization. The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. pp. 47-96. http://www.who.int/whr/2002/en/ index.html. [Accessed 18 March 2008]